April 17, 2018 / 1:13 PM / 5 months ago

BRIEF-Aequus And Camargo Complete Pre-Investigational New Drug Submission With FDA For Transdermal Anti-Nausea Program

April 17 (Reuters) - Aequus Pharmaceuticals Inc:

* AEQUUS AND CAMARGO COMPLETE PRE-INVESTIGATIONAL NEW DRUG SUBMISSION WITH FDA FOR TRANSDERMAL ANTI-NAUSEA PROGRAM

* AEQUUS - ANTICIPATES FDA FEEDBACK BY END OF APRIL, WHICH WILL DEFINE CLINICAL STRATEGY FOR REGULATORY APPROVAL IN U.S. FOR AQS1303 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below